Arcturus to supply Israel with COVID-19 vaccine candidate

Arcturus Therapeutics has signed an agreement to supply the its COVID-19 vaccine candidate, LUNAR-COV1D, to the Israeli Ministry of Health.

Delivery of the vaccine candidate is contingent upon achievement of near term clinical and regulatory milestones and other conditions to be set forth in the definitive supply agreement.

The government of Israel is responsible for distributing the vaccine to its citizens subject to approval by their Ministry of Health.

The Israeli Ministry of Health is the second government authority to reserve doses of LUNAR-COV19.

The parties intend to finalise a comprehensive supply agreement within 30 days.

Arcturus previously announced its partnership with Duke-NUS in Singapore, in which the Company recently received Clinical Trial Application (CTA) approval to proceed with a Phase 1/2 trial.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news